Business
Acacia Research Reports Third Quarter 2020 Financial Results
Company Fully Engaged in Executing Strategic Transactions in Collaboration with Starboard NEW YORK--(BUSINESS WIRE)-- Acacia Research Corporation (Nasdaq:
About this update from Acacia Research Corporation
[{"type":"text","content":"\nCompany Fully Engaged in Executing Strategic Transactions in Collaboration with Starboard\n\n NEW YORK--(BUSINESS WIRE)--\nAcacia Research Corporation (Nasdaq: ACTG) today reported results for the three-month period ended September 30, 2020.\n\nClifford Press, Chief Executive Officer, stated, “Since announcing our acquisition of the Woodford portfolio in June, we have completed dispositions that have recovered two-thirds of our purchase price. We continue to hold substantial value in the securities of public and private companies remaining in the portfolio.”\n\nHoldings of the securities of life sciences companies in the Woodford portfolio as of September 30, 2020 include:\n\n\n\nPublic Company Securities (at market value at September 30, 2020)\n\n\n\n\n\n \n\n \n\n \n \n\n\n\nCompany\n\n\n \n\nTicker\n\n\n \n\nNumber of\nShares\n\n\n \n\nValue\n\n\n\n\n\nArix Bioscience plc 1\n\n\n \n\nLSE: ARIX\n\n\n \n\n25.8 mm\n\n\n \n\n$37.0 mm\n\n\n\n\n\nSensyne Health plc\n\n\n \n\nAIM: SENS\n\n\n \n\n15.2 mm\n\n\n \n\n$11.4 mm\n\n\n\n\n\nInduction Healthcare Group plc\n\n\n \n\nAIM: INHC\n\n\n \n\n4.2 mm\n\n\n \n\n$4.0 mm\n\n\n\n\n\nOthers\n\n\n \n\n \n\n\n \n\n \n\n\n \n\n$2.1 mm\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nTotal Public Holdings\n\n\n \n\n \n\n\n \n\n \n\n\n \n\n$54.5 mm\n\n\n\n\n\n\nPrivate Company Securities (at September 30, 2020)\n\n\n\n\n\n \n\n\n\n\n\nCompany\n\n\n \n\nOwnership Percentage\n\n\n \n\nValue\n\n\n\n\n\nOxford Nanopore Technologies 2\n\n\n \n\n6%\n\n\n \n\n$108.0 mm\n\n\n\n\n\n \n\n \n \n\n\n\nNext 4 positions: \n\n\n \n\n \n\n\n \n\n \n\n\n\n\n\nImmunocore 2\n\n\n \n\n5%\n\n\n \n\n \n\n\n\n\n\nViamet Pharmaceuticals 2, 3\n\n\n \n\n26%\n\n\n \n\n \n\n\n\n\n\nAMO Pharma 2, 4\n\n\n \n\n18%\n\n\n \n\n \n\n\n\n\n\nNovaBiotics 2, 4\n\n\n \n\n4%\n\n\n \n\n$31.0 mm\n\n\n\n\n\n \n\n\n \n\n \n\n\n \n\n \n\n\n\n\n\nTotal Private Holdings\n\n\n \n\n \n\n\n \n\n$139.0 mm\n\n\n\n\n\n\n1 To be transferred to the Company in the fourth quarter of 2020 \n\n\n\n\n\n2 Value of Oxford Nanopore Technologies securities based on observed transactions during the quarter; Remaining holdings of private company securities valued at cost.\n\n\n\n\n\n3 To be transferred to the Company in the fourth quarter of 2020. \n\n\n\n\n\n4 Transferred to the Company in October.\n\n\n\n\nMr. Press added, “We are working intensively with Starboard to exec...